Przejdź do zawartości
Merck

Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.

Journal of clinical psychopharmacology (2000-06-01)
C L DeVane, J S Markowitz, S W Carson, D W Boulton, H S Gill, Z Nahas, S C Risch
ABSTRAKT

Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Ritalinic acid, 99% (CP)
Supelco
Ritalinic acid hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®